Hemostasis Today

September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Cy R. Wilkins: Treating Chemotherapy-Induced Thrombocytopenia Beyond the Platelet Count
Sep 25, 2026, 19:44

Cy R. Wilkins: Treating Chemotherapy-Induced Thrombocytopenia Beyond the Platelet Count

Cy R. Wilkins, Assistant Attending Physician of Hematology Service at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Hematology, adding:

“Does treating chemotherapy-induced thrombocytopenia actually change outcomes that matter to patients — or just the platelet count?

In our study, recently published in the American Journal of Hematology, we compared 165 romiplostim-treated patients with solid tumors and persistent CIT vs. 165 rigorously matched controls:

Takeaway:

  1. Dose intensity: Significantly fewer chemotherapy dose modifications with romiplostim (45% vs. 66%, p<0.001)
  2. Survival: No significant difference in 2-year OS overall (HR 0.80); significant mortality reduction in the metastatic subgroup (HR 0.70, p=0.02)
  3. Safety: No increased signal for VTE, arterial thrombosis, or major bleeding

Grateful to co-authors Divyash Shah, Jeffrey Zwicker, and Avi Leader.”

Title: Clinically Relevant Outcomes With Romiplostim in Patients With Solid Tumors and Persistent Chemotherapy Induced Thrombocytopenia

Authors: Cy R. Wilkins, Divyash Shah, Andriy Derkach, David Nemirovsky, Laurent Frenzel, Jodi V. Mones, Rekha Parameswaran, Emily Shteynberg, Galia Spectre, Simon Mantha, Jeffrey I. Zwicker, Avi Leader

Cy R. Wilkins

Stay updated on all scientific advances with Hemostasis Today.